Cardiff Oncology, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CRDF$0.73-4.9%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
Checking your notes…
(in thousands, except par value)
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $17,470 | $51,470 |
| Short-term investments | 40,834 | 40,276 |
| Accounts receivable and unbilled receivable | 182 | 773 |
| Prepaid expenses and other current assets | 1,642 | 2,535 |
| Total current assets | 60,128 | 95,054 |
| Property and equipment, net | 578 | 898 |
| Operating lease right-of-use assets | 629 | 1,169 |
| Other assets | 549 | 69 |
| Total Assets | $61,884 | $97,190 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,087 | $4,821 |
| Accrued liabilities | 7,577 | 7,897 |
| Operating lease liabilities | 730 | 710 |
| Total current liabilities | 16,394 | 13,428 |
| Operating lease liabilities, net of current portion | 102 | 813 |
| Total Liabilities | 16,496 | 14,241 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at December 31, 2025 and December 31, 2024 with liquidation preference of $1,117 and $1,092 at December 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.0001 par value, 150,000 shares authorized; 68,305 and 66,524 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 7 | 7 |
| Additional paid-in capital | 475,361 | 467,087 |
| Accumulated other comprehensive gain | 50 | 34 |
| Accumulated deficit | (430,030) | (384,179) |
| Total stockholders’ equity | 45,388 | 82,949 |
| Total liabilities and stockholders’ equity | $61,884 | $97,190 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.